The Oncologist

01/09/2026

Key predictors of long-term survival in advanced were identified in this study and a prognostic calculator developed that estimates survival & recurrence risk up to 10 years. Personalized EOC care is within reach.
https://doi.org/10.1093/oncolo/oyaf242

01/07/2026

Barriers to trial enrollment in acute leukemia are functionally different due to care centralization, compressed timelines, & restrictive designs. This qualitative study by highlights actionable solutions like decentralization, peer support, & flexible eligibility.
https://doi.org/10.1093/oncolo/oyaf241

01/06/2026

An important ➖ trial. mut metastatic cancer relies on signaling; This ph2 trial tested + but showed 0️⃣ response, 56% , 4.0 mo and 6.2 mo mOS. The combo had limited toxicity but was ultimately ineffective.
https://doi.org/10.1093/oncolo/oyaf400

01/02/2026

N=1,678 patients on showed mostly low-grade and 🩸 tox. 🤢neutropenia, and 🥱were common. 🫁🔥occurred in ~11–12%. Dose changes were frequent, underscoring the need for proactive management

AbstractBackground. Trastuzumab deruxtecan (T-DXd), an approved human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugate, may cause

12/24/2025

Although yields high responses in LARC this paper describes 3️⃣ cases with progression on . All were with high . revealed -high profiles linked to worse response. All achieved NED after salvage therapy

Abstract. Six months of treatment with dostarlimab followed by nonoperative management in case of clinical complete response (cCR) is the new standard-of-c

12/22/2025

Patients with hematologic malignancies residing in socioeconomically disadvantaged areas are significantly less likely to receive CAR T-cell therapy. Focused interventions are necessary to ensure equitable access to cellular therapies.

Abstract. Chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory hematologic malignancies demands numerous visits, which ma

12/18/2025

Cancer trials collect extensive AE data—but key info to understand tolerability is missing. REVIEW HIGHLIGHT - improved capture and reporting of low-grade toxicities, adherence, and the patient voice make AE reporting more meaningful

AbstractImportance. The current methods to capture and report adverse events (AEs) in clinical trials were developed in the era of cytotoxic chemotherapy a

12/17/2025

Based on the FAERS database, this study summarized the characteristics of antibody-drug conjugate (ADC)-related interstitial lung disease (ILD) events. Eight ADCs have significant correlations with ILD in both disproportionality and Bayesian analyses. Patients receiving trastuzumab deruxtecan exhibited the highest risk of ILD.
https://doi.org/10.1093/oncolo/oyaf228

12/16/2025

Hot take on smoldering myeloma: despite positive trials, early daratumumab prevents lab abnormalities—not meaningful morbidity. Modern surveillance vs. early intervention: the debate continues.
https://doi.org/10.1093/oncolo/oyaf216

12/15/2025

Effect of HLA restriction on racial and ethnic disparities in access to immune therapies for advanced synovial sarcoma
https://doi.org/10.1093/oncolo/oyaf193

12/12/2025

Identity matters! Patients with instead of had reduced cost, ambulatory use with dramatic difference (10.2 vs 30.7 mo) despite similar tolerance of . Reflexive genomic testing at diagnosis may improve outcomes

AbstractBackground. There is limited evidence regarding the economic burden, treatment patterns, and overall survival (OS) of patients with cholangiocarcin

12/11/2025

Imatinib-associated severe skin rash poses a challenge in the management of gastrointestinal stromal tumors. This study demonstrates that personalized desensitization therapy assisted with therapeutic drug monitoring effectively enables most patients to resume imatinib.

AbstractBackground. Skin rash is one of the most common imatinib-associated adverse events in patients with gastrointestinal stromal tumors (GISTs), potent